Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2025 > Vol 6, №1 (2025) > Obesity and metabolic dysfunction in pathogenesis of pelvic organ prolapse

Obesity and metabolic dysfunction in pathogenesis of pelvic organ prolapse

Mekan R. Orazov , Viktor E. Radzinsky , Farida F. Minnullina

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Pelvic organ prolapse (POP) has a considerable negative effect on the women’s quality of life. The rate of POP will grow due to population ageing (according to forecasts, by 46% by the year 2050). The global prevalence of obesity is increasing dramatically: according to the WHO forecasts, more than 50% of the Earth’s population (more than 4 billion people) will be overweight or obese by the year 2035. Obesity and dyslipidemia (elevated levels of triglycerides, low-density lipoprotein cholesterol; decreased levels of high-density lipoproteins) can trigger the development and progression of POP. However, this aspect of the POP pathogenesis is poorly understood.
Aim: to expand the knowledge about the POP pathogenesis in patients with obesity and metabolic disorders.
Methods. Analysis of the results of the studies published in the CochraneLibrary, PubMed, Science Direct, ELibrary digital libraries in 2010–2024 for the keywords  “pelvic organ prolapse/пролапс тазовых органов”, “recurrence/рецидив”, “pathogenesis/патогенез”, “metabolic syndrome/метаболический синдром”, “abdominal obesity/абдоминальное ожирение”, “hypertriglyceridemia/гипертриглицеридемия”, “hypercholesterolemia/гиперхолестеринемия” was performed.
Results. Coupled with the mechanical load caused by abdominal obesity, chronic systemic inflammation associated with metabolic syndrome, elevated levels of pro-inflammatory cytokines and activation of matrix metalloproteinases, as well as oxidative stress can result in weakening of the pelvic organ supportive structures, and microvascular dysfunction disturbes local hemodynamics, thereby contributing to the pelvic floor connective tissue remodeling processes. 
Conclusion. Qualitative studies involving large samples are necessary for better understanding of the pathogenetic mechanisms underlying the development of primary POP and POP recurrence, as well as for the development of the treatment approaches contributing to reducing the risk of progression. The management tactics for patients with POP associated with metabolic syndrome requires a multidisciplinary approach. 
Keywords: pelvic organ prolapse, recurrence, pathogenesis, metabolic syndrome, abdominal obesity, dyslipidemia.

About the Author

Mekan R. Orazov 1 , Viktor E. Radzinsky 1 , Farida F. Minnullina 2

1 Patrice Lumumba People’s Friendship University of Russia (RUDN University), Moscow, Russia

2 Kazan (Volga Region) Federal University, Kazan, Russia

References

1. Pang H, Zhang L, Han S et al. A nationwide population-based survey on the prevalence and risk factors of symptomatic pelvic organ prolapse in adult women in China – a pelvic organ prolapse quantification system-based study. BJOG 2021;128(8):1313-23.
2. Wu JM, Matthews CA, Conover MM et al. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol 2014;123(6):1201-6.
3. Larouche M, Belzile E, Geoffrion R. Surgical management of symptomatic apical pelvic organ prolapse: a systematic review and meta-analysis. Obstet Gynecol 2021;137:1061-73.
4. American College of Obstetricians and Gynecologists, the American Urogynecologic Society. This Practice Bulletin is updated as highlighted to reflect the US Food and Drug Administration order to stop the sale of transvaginal synthetic mesh products for the repair of pelvic organ prolapse, Pelvic Organ Prolapse. Female Pelvic Med Reconstr Surg 2019;25:397-408.
5. Zhou Q, Lu M, Li GS et al. Identification of potential molecular mechanisms and therapeutic targets for recurrent pelvic organ prolapse. Heliyon 2023;9(9):e19440.
6 Kurki A, Paakinaho K, Hannula M et al. Promoting cell proliferation and collagen production with ascorbic acid 2-phosphate-releasing poly(l-lactide-co-ε-caprolactone) membranes for treating pelvic organ prolapse. Regen Biomater 2024;11:rbae060.
7. Vergeldt TF, Weemhoff M, IntHout J, Kluivers KB. Risk factors for pelvic organ prolapse and its recurrence: a systematic review. Int Urogynecol J 2015;26(11):1559-73.
8. Schulten SFM, Claas-Quax MJ, Weemhoff M et al. Risk factors for primary pelvic organ prolapse and prolapse recurrence: an updated systematic review and meta-analysis. Am J Obstet Gynecol 2022;227(2):192-208.
9. Лавренова Е.А., Драпкина О.М. Инсулинорезистентность при ожирении: причины и последствия. Ожирение и метаболизм. 2020;17:1:48-55.
Lavrenova E.A., Drapkina O.M. Insulin resistance in obesity: causes and consequences. Obesity and metabolism. 2020;17:1:48-55 (in Russian).
10. Dietz HP. The aetiology of prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(10):1323-9.
11. Rogowski A, Bienkowski P, Tarwacki D et al. Association between metabolic syndrome and pelvic organ prolapse severity. Int Urogynecol J 2015;26(4):563-8.
12. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013;34(31):2436-43.
13. Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost 2013;110(4):669-80.
14. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010;12(4):e157-e180.
15. Lee UJ, Kerkhof MH, van Leijsen SA, Heesakkers JP. Obesity and pelvic organ prolapse. Curr Opin Urol 2017 Sep;27(5):428-34.
16. Giri A, Hartmann KE, Hellwege JN et al. Obesity and pelvic organ prolapse: a systematic review and meta-analysis of observational studies. Am J Obstet Gynecol 2017;217(1):11-26.e3.
17. Shalom DF, Lin SN, St Louis S, Winkler HA. Effect of age, body mass index, and parity on Pelvic Organ Prolapse Quantification system measurements in women with symptomatic pelvic organ prolapse. J Obstet Gynaecol Res 2012;38(2):415-9.
18. Washington BB, Erekson EA, Kassis NC, Myers DL. The association between obesity and stage II or greater prolapse. Am J Obstet Gynecol 2010;202(5):503.e1-503.e4
19. Kim YH, Kim JJ, Kim SM et al. Association between metabolic syndrome and pelvic floor dysfunction in middle-aged to older Korean women. Am J Obstet Gynecol 2011;205(1):71.e1-71.e8
20. Bolanowski J, Bronowicz J, Bolanowska B et al. Impact of education and place of residence on the risk of metabolic syndrome in Polish men and women. Int J Cardiol 2010;145(3):542-4.
21. Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol 2013;10(11):648-61.
22. Gava G, Alvisi S, Mancini I et al. Prevalence of metabolic syndrome and its components in women with and without pelvic organ prolapse and its association with prolapse severity according to the Pelvic Organ Prolapse Quantification system. Int Urogynecol J 2019;30(11):1911-7.
23. Wang L, Cao Y, Li P et al. Relationship between pelvic floor muscle function and insulin resistance among non-diabetic females: a 3d ultrasound evaluation. J Obstet Gynaecol 2024;44(1):2381569.
24. Xiong Z, Yuan C, Yang M et al. Risk Factors for Pelvic Organ Prolapse: Wide-Angled Mendelian Randomization Analysis. Int Urogynecol J 2024;35(7):1405-11.
25. Si K, Yang Y, Liu Q et al. Association of Central and General Obesity Measures With Pelvic Organ Prolapse. Obstet Gynecol 2025;145(1):108-14. DOI: 10.1097/AOG.00000000000057582024
26. Saei Ghare Naz M, Ramezani Tehrani F, Behroozi-Lak T et al. Polycystic Ovary Syndrome and Pelvic Floor Dysfunction: A Narrative Review. Res Rep Urol 2020;12:179-85.
27. Tian Z, Wang X, Hu X, Sun Z. Effect of Surgically Induced Weight Loss on Pelvic Organ Prolapse: A Meta-analysis. Obes Surg 2023;33(11):3402-10.
28. Lian W, Zheng Y, Huang H et al. Effects of bariatric surgery on pelvic floor disorders in obese women: a meta-analysis. Arch Gynecol Obstet 2017;296(2):181-9.
29. Mohamed F, Jeram M, Coomarasamy C et al. Does Bariatric Surgery Improve Faecal Incontinence? A Systematic Review and Meta-analysis. Obes Surg 2021;31(7):2942-53.
30. Boyd SS, Exume D, Long JB et al. Effect of Body Mass Index on Complications After Vaginal and Laparoscopic Apical Prolapse Surgery. Int Urogynecol J 2024;35(8):1593-8.
31. Нарушения липидного обмена. Клинические рекомендации Минздрава России. М., 2023.
Disorders of lipid metabolism. Clinical recommendations of the Ministry of Health of Russia. Moscow, 2023 (in Russian).
32. Chen YP, Lo TS, Chien YH et al. In Vitro and In Vivo Drug Release from a Nano-Hydroxyapatite Reinforced Resorbable Nanofibrous Scaffold for Treating Female Pelvic Organ Prolapse. Polymers (Basel) 2024;16(12):1667.
33. Ringel NE, Lenger SM, High R et al. Effects of Obesity on Urogynecologic Prolapse Surgery Outcomes: A Systematic Review and Meta-analysis. Obstet Gynecol 2024;143(4):539-49.

For citation:Orazov M.R., Radzinsky V.E., Minnullina F.F. Obesity and metabolic dysfunction in pathogenesis of pelvic organ prolapse. Clinical review for general practice. 2025; 6 (1): 99–104 (In Russ.). DOI: 10.47407/kr2024.6.1.00557


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru